Literature DB >> 21393996

Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer.

Kerstin Rönsch1, Marcel Jäger, Anja Schöpflin, Mihai Danciu, Silke Lassmann, Andreas Hecht.   

Abstract

Aberrant Wnt/β-catenin signaling is a driving force during initiation and progression of colorectal cancer. Yet, the Wnt/β-catenin targets CDX1, EPHB2, EPHB3 and EPHB4 (EPHB2-4) act as tumor suppressors in intestinal epithelial cells and frequently appear to be transcriptionally silenced in carcinomas. The molecular mechanisms which underlie the apparent loss of expression of a subset of Wnt/β-catenin targets in a background of persistent pathway activity are largely unknown. To gain insight into this, we quantified expression of CDX1 and EPHB2-4 in human tissue specimens of case-matched colorectal normal mucosa, adenoma and invasive carcinoma. In particular EPHB2-4 display biphasic, albeit not strictly coincident, expression profiles with elevated levels in adenomas and decreased transcription in approximately 30% of the corresponding carcinomas. Consistent with their divergent and variable expression we observed considerable heterogeneity among the epigenetic landscapes at CDX1 and EPHB2-4 in a model of colorectal carcinoma cell lines. Unlike the inactive CDX1 locus, EPHB2-4 maintain DNA hypomethylation of their promoter regions in the silent state. A strong reduction of active histone modifications consistently parallels reduced expression of CDX1 and EPHB3 and to some extent of EPHB2. Accordingly, treatment with inhibitors for DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) restored CDX1 and EPHB2-4 expression depending upon epigenetic features at their promoters but also upon cellular background. Overall our findings show that downregulation of CDX1 and EphB receptor genes occurs independently and that different branches of epigenetic control systems including class I and III HDACs contribute to epigenetic silencing of Wnt/β-catenin targets during colorectal tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21393996     DOI: 10.4161/epi.6.5.15300

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  13 in total

Review 1.  Therapeutic targeting of EPH receptors and their ligands.

Authors:  Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

2.  Receptor Tyrosine Kinase EphB3: a Prognostic Indicator in Colorectal Carcinoma.

Authors:  Zhuoqi Xuan; Jianming Huang; Lin Gao; Yong Wang; Jiandong Wang; Yueming Sun
Journal:  Pathol Oncol Res       Date:  2018-12-07       Impact factor: 3.201

Review 3.  Epigenetic Biomarkers in Colorectal Cancer.

Authors:  Mukesh Verma; Vineet Kumar
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

4.  SNAIL1 combines competitive displacement of ASCL2 and epigenetic mechanisms to rapidly silence the EPHB3 tumor suppressor in colorectal cancer.

Authors:  Kerstin Rönsch; Sabine Jägle; Katja Rose; Maximilian Seidl; Francis Baumgartner; Vivien Freihen; Afsheen Yousaf; Eric Metzger; Silke Lassmann; Roland Schüle; Robert Zeiser; Tom Michoel; Andreas Hecht
Journal:  Mol Oncol       Date:  2014-09-16       Impact factor: 6.603

5.  Energy homeostasis targets chromosomal reconfiguration of the human GH1 locus.

Authors:  Hana Vakili; Yan Jin; Peter A Cattini
Journal:  J Clin Invest       Date:  2014-10-08       Impact factor: 14.808

6.  Negative regulation of human growth hormone gene expression by insulin is dependent on hypoxia-inducible factor binding in primary non-tumor pituitary cells.

Authors:  Hana Vakili; Yan Jin; Peter A Cattini
Journal:  J Biol Chem       Date:  2012-07-25       Impact factor: 5.157

Review 7.  Epigenetic Biomarkers for the Early Detection of Gastrointestinal Cancer.

Authors:  Hui-Mi Chen; Jing-Yua Fang
Journal:  Gastrointest Tumors       Date:  2015-04-15

8.  Silencing of the EPHB3 tumor-suppressor gene in human colorectal cancer through decommissioning of a transcriptional enhancer.

Authors:  Sabine Jägle; Kerstin Rönsch; Sylvia Timme; Hana Andrlová; Miriam Bertrand; Marcel Jäger; Amelie Proske; Monika Schrempp; Afsheen Yousaf; Tom Michoel; Robert Zeiser; Martin Werner; Silke Lassmann; Andreas Hecht
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-18       Impact factor: 11.205

9.  Epigenetic Control of the Notch and Eph Signaling Pathways by the Prion Protein: Implications for Prion Diseases.

Authors:  Théo Z Hirsch; Séverine Martin-Lannerée; Fabienne Reine; Julia Hernandez-Rapp; Laetitia Herzog; Michel Dron; Nicolas Privat; Bruno Passet; Sophie Halliez; Ana Villa-Diaz; Caroline Lacroux; Victor Klein; Stéphane Haïk; Olivier Andréoletti; Juan-Maria Torres; Jean-Luc Vilotte; Vincent Béringue; Sophie Mouillet-Richard
Journal:  Mol Neurobiol       Date:  2018-07-11       Impact factor: 5.590

10.  EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.

Authors:  Lin Li; Na Xu; Jin-Fang Zhang; Lu-Lu Xu; Xuan Zhou; Bin-Tao Huang; Yu-Ling Li; Xiao-Li Liu
Journal:  Int J Med Sci       Date:  2016-04-28       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.